Cover Image
市場調查報告書

非酒精性脂肪性肝炎治療藥市場 - 全球產業分析、規模、佔有率、成長、趨勢及未來預測

Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025

出版商 Transparency Market Research 商品編碼 357891
出版日期 內容資訊 英文 65 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非酒精性脂肪性肝炎治療藥市場 - 全球產業分析、規模、佔有率、成長、趨勢及未來預測 Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025
出版日期: 2016年04月15日 內容資訊: 英文 65 Pages
簡介

非酒精性脂肪肝,是幾乎或完全不攝取酒精的人的肝臟有過剩脂肪特徵的疾病,直接原因不明。可是肥胖和胰島素抗性有很大關聯。

本報告提供全球非酒精性脂肪性肝炎治療藥市場相關調查,市場現狀與未來發展預測,各藥物、地區趨勢,及參與企業簡介彙整。

第1章 簡介

第2章 摘要整理

第3章 非酒精性脂肪性肝炎治療藥市場

  • 簡介
  • 非酒精性脂肪性肝炎的流行病學
    • 北美
    • 歐洲
    • 亞太地區
    • 其他
  • 診斷和治療
  • 市場趨勢
    • 阻礙要素
    • 市場機會

第4章 各藥物市場

  • 概要
  • 第三階段的潛在性藥物候補
    • Obeticholic Acid(OCA)
    • Aramchol
    • Saroglitazar
    • Elafibranor
  • 開發平台分析
  • 各地區目標人群

第5章 建議

第6章 企業簡介

  • AstraZeneca plc
  • Intercept Pharmaceuticals Inc.
  • Galmed Pharmaceuticals
  • GENFIT SA
  • Gilead Sciences Inc.
  • Zydus Cadila
  • Immuron Ltd.
  • Conatus Pharmaceuticals
  • Tobira Therapeutics Inc.
  • 其他
目錄

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years up to 20% of patients with NASH develop cirrhosis of the liver, and 10% die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Thus, there is an urgent need for effective treatment options for these diseases. The need for treatment is expected to propel the growth of NASH therapeutics in coming years.

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report provides a list of the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market followed by Obeticholic Acid (OCA) market and the market for Elafibranor is expected to grow at the highest CAGR.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes epidemiology of Nonalcoholic steatohepatitis (NASH) by region, to provide a thorough analysis of the overall addressable global market for the NASH therapeutics. Moreover, the report provides qualitative information about diagnosis and treatment of NASH.

The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the NASH market across different regions worldwide. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments.

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

  • Overview
  • Potential Drug Candidates in Phase III
  • Obeticholic Acid (OCA)
  • Aramchol (arachidyl amido cholanoic acid)
  • Saroglitazar
  • Elafibranor

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation
  • 1.4. Assumptions

Chapter 2 - Executive Summary

  • 2.1. Global NASH Market, by Drug, 2025(US$ Mn)

Chapter 3 - Global Nonalcoholic Steatohepatitis(NASH) Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Epidemiology of Nonalcoholic Steatohepatitis(Qualitative Analysis)
    • 3.2.1. North America
    • 3.2.2. Europe
    • 3.2.3. Asia Pacific
    • 3.2.4. Rest of World
  • 3.3. Diagnosis and Treatment of NASH(Qualitative Analysis)
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

Chapter 4 - Global Nonalcoholic Steatohepatitis(NASH) Therapeutics Market, By Drug Type, 2015-2025(US$ Mn)

  • 4.1. Overview
  • 4.2. Potential Drug Candidates in Phase III
    • 4.2.1. Obeticholic Acid(OCA)
    • 4.2.2. Aramchol(arachidyl amido cholanoic acid)
    • 4.2.3. Saroglitazar
    • 4.2.4. Elafibranor
  • 4.3. Pipeline Analysis
    • 4.3.1. Tabular Representation of Phase I and Phase II Clinical Trials(Qualitative Analysis)
  • 4.4. Target Population By Geography: NASH Market

Chapter 5 Recommendations

Chapter 6 Company Profiles

  • 6.1. AstraZeneca plc
    • 6.1.1. Company Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Product Pipeline
    • 6.1.4. Business Strategies
    • 6.1.5. Recent Developments
  • 6.2. Intercept Pharmaceuticals Inc.
  • 6.3. Galmed Pharmaceuticals
  • 6.4. GENFIT SA
  • 6.5. Gilead Sciences Inc.
  • 6.6. Zydus Cadila
  • 6.7. Immuron Ltd.
  • 6.8. Conatus Pharmaceuticals
  • 6.9. Tobira Therapeutics Inc.
  • 6.10. Others
Back to Top